PAS
NVO

Park Avenue Securities’s Novo Nordisk NVO Stock Holding History

Park Avenue Securities’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
46,721
+4,473
+11% +$192K 0.01% 635
2026
Q1 		$1.55M Sell
42,248
-3,087
-7% -$146K 0.01% 651
2025
Q4 		$2.31M Sell
45,335
-19,852
-30% -$1.02M 0.02% 501
2025
Q3 		$3.62M Sell
65,187
-20,783
-24% -$1.22M 0.03% 391
2025
Q2 		$5.93M Buy
+85,970
New +$5.85M 0.05% 246
2025
Q1 		– Sell
-102,657
Closed -$8.83M – 1420
2024
Q4 		$8.83M Buy
102,657
+7,103
+7% +$768K 0.09% 153
2024
Q3 		$11.4M Sell
95,554
-15,217
-14% -$2.03M 0.13% 113
2024
Q2 		$15.8M Buy
110,771
+7,832
+8% +$1.04M 0.19% 77
2024
Q1 		$13.2M Buy
102,939
+14,775
+17% +$1.76M 0.17% 87
2023
Q4 		$9.12M Buy
88,164
+3,359
+4% +$332K 0.13% 107
2023
Q3 		$7.71M Buy
84,805
+4,769
+6% +$420K 0.12% 113
2023
Q2 		$6.48M Buy
80,036
+3,966
+5% +$324K 0.1% 129
2023
Q1 		$6.05M Sell
76,070
-48
-0.1% -$3.4K 0.1% 128
2022
Q4 		$5.15M Buy
76,118
+804
+1% +$47.1K 0.09% 142
2022
Q3 		$3.75M Buy
75,314
+4,142
+6% +$222K 0.07% 165
2022
Q2 		$3.96M Buy
71,172
+20,824
+41% +$1.16M 0.08% 162
2022
Q1 		$2.8M Buy
50,348
+19,188
+62% +$985K 0.05% 217
2021
Q4 		$1.75M Buy
31,160
+556
+2% +$30.1K 0.03% 303
2021
Q3 		$1.47M Buy
30,604
+3,612
+13% +$175K 0.03% 298
2021
Q2 		$1.13M Buy
26,992
+4,854
+22% +$188K 0.02% 345
2021
Q1 		$746K Buy
22,138
+3,976
+22% +$142K 0.02% 461
2020
Q4 		$634K Buy
18,162
+2,390
+15% +$82.6K 0.02% 443
2020
Q3 		$548K Buy
15,772
+2,134
+16% +$71.1K 0.02% 412
2020
Q2 		$447K Buy
+13,638
New +$435K 0.02% 407
2020
Q1 		– Sell
-8,992
Closed -$260K – 504
2019
Q4 		$260K Sell
8,992
-2,944
-25% -$81.5K 0.01% 503
2019
Q3 		$309K Buy
+11,936
New +$302K 0.01% 402
2019
Q2 		– Sell
-10,266
Closed -$268K – 405
2019
Q1 		$268K Buy
+10,266
New +$252K 0.01% 337

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Park Avenue Securities's NVO Position: Q2 2026 in Review

Park Avenue Securities increased its Novo Nordisk (NVO) stake by 11% in Q2 2026, buying an estimated $192K and bringing the position to 46,721 shares worth $2.24M. The position accounts for 0.01% of the portfolio, ranked #635.

Park Avenue Securities first reported a position in NVO in Q1 2019 and has held it in 27 quarters since. The position peaked at $15.8M in Q2 2024. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Park Avenue Securities held 46,721 shares of Novo Nordisk worth $2.24M as of Q2 2026.
  • Park Avenue Securities bought 4,473 Novo Nordisk shares in Q2 2026, an estimated $192K.
  • Novo Nordisk made up 0.01% of Park Avenue Securities's portfolio in Q2 2026, its #635 holding.
  • Park Avenue Securities first reported a position in Novo Nordisk in Q1 2019 and has held it in 27 quarters since.
  • Park Avenue Securities's Novo Nordisk position peaked at $15.8M in Q2 2024.
  • 387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.